後線治療Phase 3 RCTLancet 2025來源:人工整理
Zanzalintinib + Atezolizumab vs Regorafenib (3L+ MSS/pMMR mCRC)
關鍵結果ITT mOS 10.9 vs 9.4 mo (HR 0.80, 95% CI 0.69–0.93, p=0.0045); no liver mets interim HR 0.79 (p=0.087, NS); G3+ TRAEs 60% vs 37%
首個在 MSS/pMMR mCRC 以免疫療法組合達 Phase 3 OS 獲益(vs regorafenib),突破 MSS 免疫治療壁壘,但毒性顯著較高。
詳細證據整理
Zanzalintinib plus Atezolizumab versus Regorafenib in Refractory Metastatic Colorectal Cancer (STELLAR-303)
Abstract
Design: Global Phase 3 randomized controlled trial in patients with refractory (third-line or later) microsatellite-stable / mismatch-repair-proficient (MSS/pMMR) metastatic colorectal cancer (mCRC) who had progressed on or were intolerant to standard therapies.
Arms: Patients (N = 901) were randomized to:
- Experimental: zanzalintinib (a multitargeted tyrosine kinase inhibitor of MET/VEGFR/AXL/MER/RET) + atezolizumab (anti-PD-L1)
- Control: regorafenib
Primary endpoint: Overall survival (OS) in the intention-to-treat (ITT) population and OS in the subset of patients without liver metastases.
Key Results
| Endpoint | Zanzalintinib + Atezolizumab | Regorafenib |
|---|---|---|
| Median OS (ITT) | 10.9 months | 9.4 months |
| OS HR (ITT) | 0.80 (95% CI 0.69–0.93; P=0.0045) | |
| OS HR (no liver metastases, interim) | 0.79 (P=0.087, not significant; final analysis pending) | |
| Grade ≥3 treatment-related AEs | 60% | 37% |
Conclusions
STELLAR-303 is the first Phase 3 trial to demonstrate a statistically significant overall survival benefit for an immunotherapy-based combination versus regorafenib in MSS/pMMR metastatic colorectal cancer, challenging the long-held view that MSS mCRC does not respond to immune checkpoint inhibition. Zanzalintinib is hypothesized to remodel the tumor immune microenvironment, acting synergistically with PD-L1 blockade. The OS improvement (HR 0.80) is modest relative to current third-line standards such as SUNLIGHT (TAS-102 + bevacizumab, HR 0.61) and FRESCO-2 (fruquintinib, HR 0.66), and toxicity was notably higher (Grade ≥3 treatment-related AEs 60% vs 37%). The no-liver-metastases subset did not reach significance at interim analysis. Despite these caveats, the study is an important milestone that may drive a new wave of research into later-line immunotherapy for MSS mCRC.
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
相關評論
社論Med 2026
STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer.
Bando 與 Yoshino 評論:STELLAR-303 是 MSS mCRC 首個達到 OS 獲益的免疫治療 Phase 3,可能重塑後線治療並帶動 biomarker 導向的 MSS 免疫治療研究
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…